Treatment News : Merck’s Hep C Drugs Show Promise for HIV Coinfection

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » March 2014

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

March 8, 2014

Merck’s Hep C Drugs Show Promise for HIV Coinfection

CROI 2014Promising preliminary results from a trial of Merck’s MK-5172 and MK-8742, given with or without ribavirin, showed that the combination therapy was as safe in treating genotype 1 of hepatitis C virus (HCV) among those coinfected with HIV as it was among those monoinfected with hep C. The treatment appears to boast near-perfect success rates. Results from the C-WORTHY study, which is a Phase II, randomized, dose-responsive, parallel-group, multiple-site, open-label trial comparing various difficult-to-treat populations among a group of 450 people with hep C, were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.

The coinfected segment of the study included 59 people coinfected with HIV and genotype 1 of HCV who were treatment naive, did not have cirrhosis and who were taking a stable antiretroviral regimen to treat HIV: Isentress (raltegravir) and Viread (tenofovir) or Ziagen (abacavir) with either Epivir (3TC) or Emtriva (emtricitabine ) These participants were compared with 65 people monoinfected with genotype 1 of hep C. All the participants were randomized to receive the NS3/4A protease inhibitor MK-5172 and the NS5A replication complex inhibitor MK-8742 for 12 weeks either with or without ribavirin.

At the end of treatment, all 29 of the coinfected participants who took ribavirin and 90 percent of those who did not (26/29) had undetectable hep C. Meanwhile, among the monoinfected participants, 94 percent of those who took ribavirin (49/52) and all 13 of those who did not achieved an undetectable viral count.

Twelve weeks must pass after the end of treatment for researchers to determine if a participant has been cured of hep C. Merck intends to present such results at a meeting in the spring.

Of the three coinfected participants who failed treatment, one completed the therapy but was then lost to follow-up, and two others maintained low levels of one or both of MK-5172 and MK-8742 and experienced virologic breakthrough at the eight-week mark during treatment.

The most common adverse side effects were fatigue (7 percent) and headache (8 percent). There was no difference in side effects between the coinfected and monoinfected groups.

To read the Merck press release, click here.

Search: Merck, hepatitis C, HCV, coinfection, HIV, MK-5172, MK-8742, C-WORTHY, Isentress, ralegravir, Viread, tenofovir, Ziagen, abacavir, Epivir, 3TC, Emtriva, emtricitabine, monoinfection, CROI


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    adorableone
    New York
    New York


    TanyaB
    Delray Beach
    Florida


    ernienyc
    Bronx
    New York


    RayOctober
    Richmond
    Virginia
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Will decriminalizing injection drug use help end the global HIV epidemic?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.